JP2016505018A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505018A5
JP2016505018A5 JP2015552834A JP2015552834A JP2016505018A5 JP 2016505018 A5 JP2016505018 A5 JP 2016505018A5 JP 2015552834 A JP2015552834 A JP 2015552834A JP 2015552834 A JP2015552834 A JP 2015552834A JP 2016505018 A5 JP2016505018 A5 JP 2016505018A5
Authority
JP
Japan
Prior art keywords
individual
combination according
combination
paclitaxel
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505018A (ja
JP6342918B2 (ja
Filing date
Publication date
Priority claimed from US13/794,480 external-priority patent/US9511046B2/en
Application filed filed Critical
Publication of JP2016505018A publication Critical patent/JP2016505018A/ja
Publication of JP2016505018A5 publication Critical patent/JP2016505018A5/ja
Application granted granted Critical
Publication of JP6342918B2 publication Critical patent/JP6342918B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552834A 2013-01-11 2014-01-10 膵臓がんの処置方法 Active JP6342918B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361751820P 2013-01-11 2013-01-11
US61/751,820 2013-01-11
US201361752355P 2013-01-14 2013-01-14
US61/752,355 2013-01-14
US13/794,480 2013-03-11
US13/794,480 US9511046B2 (en) 2013-01-11 2013-03-11 Methods of treating pancreatic cancer
PCT/US2014/011145 WO2014110443A1 (en) 2013-01-11 2014-01-10 Methods of treating pancreatic cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018028611A Division JP6697017B2 (ja) 2013-01-11 2018-02-21 膵臓がんの処置方法

Publications (3)

Publication Number Publication Date
JP2016505018A JP2016505018A (ja) 2016-02-18
JP2016505018A5 true JP2016505018A5 (enExample) 2017-02-16
JP6342918B2 JP6342918B2 (ja) 2018-06-13

Family

ID=51165317

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015552834A Active JP6342918B2 (ja) 2013-01-11 2014-01-10 膵臓がんの処置方法
JP2018028611A Active JP6697017B2 (ja) 2013-01-11 2018-02-21 膵臓がんの処置方法
JP2019033910A Pending JP2019081790A (ja) 2013-01-11 2019-02-27 膵臓がんの処置方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018028611A Active JP6697017B2 (ja) 2013-01-11 2018-02-21 膵臓がんの処置方法
JP2019033910A Pending JP2019081790A (ja) 2013-01-11 2019-02-27 膵臓がんの処置方法

Country Status (25)

Country Link
US (3) US9511046B2 (enExample)
EP (1) EP2943192B9 (enExample)
JP (3) JP6342918B2 (enExample)
KR (1) KR102205710B1 (enExample)
CN (2) CN105025893A (enExample)
AU (1) AU2013203699B2 (enExample)
BR (1) BR112015016681A8 (enExample)
CA (1) CA2897589C (enExample)
CY (1) CY1124273T1 (enExample)
DK (1) DK2943192T3 (enExample)
ES (1) ES2878145T3 (enExample)
HK (1) HK1216853A1 (enExample)
HR (1) HRP20211062T1 (enExample)
HU (1) HUE056612T2 (enExample)
IL (2) IL239739A0 (enExample)
LT (1) LT2943192T (enExample)
MX (1) MX382017B (enExample)
NZ (2) NZ734971A (enExample)
PL (1) PL2943192T3 (enExample)
PT (1) PT2943192T (enExample)
RS (1) RS62076B1 (enExample)
SI (1) SI2943192T1 (enExample)
SM (1) SMT202100377T1 (enExample)
WO (1) WO2014110443A1 (enExample)
ZA (1) ZA201504877B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
CA2801891C (en) * 2010-06-07 2020-10-27 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
AU2012249371B2 (en) 2011-04-28 2017-06-08 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
PL2790675T3 (pl) 2011-12-14 2019-12-31 Abraxis Bioscience, Llc Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス, エルエルシー 肺がんを処置する方法
JP6309610B2 (ja) 2013-03-14 2018-04-11 アブラクシス バイオサイエンス, エルエルシー 膀胱がんを処置する方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
JP6758325B2 (ja) 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド タキサン粒子およびその使用
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
EP3316871A4 (en) * 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
WO2018169779A1 (en) * 2017-03-17 2018-09-20 ImClone, LLC Combination therapy for pancreatic cancer
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
GB201908352D0 (en) * 2019-06-11 2019-07-24 Innovation Ulster Ltd Sonodynamic therapy
WO2021022256A1 (en) * 2019-08-01 2021-02-04 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
IL292439B2 (en) 2019-10-28 2026-05-01 Abraxis Bioscience Llc Pharmaceutical preparations of albumin and rapamycin
EP4100035A1 (en) * 2020-02-04 2022-12-14 Swedish Orphan Biovitrum AB (publ) Pdac treatment regimen
AU2023435819A1 (en) * 2023-03-09 2025-10-02 Minneamrita Therapeutics Llc Drug combination for treatment of pancreatic cancer
CN117099681B (zh) * 2023-08-28 2024-07-05 南京农业大学 一种利用紫杉醇加倍玉米单倍体的方法
AU2025207356A1 (en) 2024-01-11 2026-08-06 Minneamrita Therapeutics Llc Triptolide formulations

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
WO1999000113A1 (en) 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
CA2155947C (en) 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents
CA2371912C (en) 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
KR20140148502A (ko) 2002-12-09 2014-12-31 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
AU2012201568B2 (en) 2005-02-18 2014-07-31 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CA2604473A1 (en) 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
JP2007297339A (ja) * 2006-04-29 2007-11-15 Torii Yakuhin Kk 癌を治療又は検査するための医薬
AU2006347740A1 (en) 2006-08-31 2008-03-06 Abraxis Bioscience, Llc Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP3417859A1 (en) 2007-03-07 2018-12-26 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
WO2009126175A1 (en) 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
CA2721153C (en) 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
ES2588194T3 (es) * 2008-04-11 2016-10-31 Seattle Genetics, Inc. Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres
AU2009324464B2 (en) 2008-12-11 2016-05-05 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
BRPI1008955A2 (pt) 2009-03-13 2015-09-01 Abraxis Bioscience Llc Terapia de combinação com derivados de tiocolchicina.
MX2011010673A (es) 2009-04-10 2012-02-21 Abraxis Bioscience Llc Formulaciones de nanoparticulas y usos de las mismas.
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
US8383358B2 (en) * 2009-05-28 2013-02-26 Abraxis Bioscience, Llc Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy
BR112012004149A2 (pt) * 2009-08-25 2016-03-22 Abraxis Bioscience Llc terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog
JP2011079788A (ja) * 2009-10-08 2011-04-21 Oita Univ 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬
MX342641B (es) * 2010-01-05 2016-10-07 Vascular Biogenics Ltd Metodos para uso de un agente adenoviral anti-angiogenico especifico.
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
WO2011121453A2 (en) 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
CN103221042B (zh) 2010-06-02 2016-02-10 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
CA2801891C (en) 2010-06-07 2020-10-27 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
AU2012249371B2 (en) 2011-04-28 2017-06-08 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
PL2790675T3 (pl) 2011-12-14 2019-12-31 Abraxis Bioscience, Llc Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014123612A1 (en) 2013-02-11 2014-08-14 Abraxis Bioscience, Llc Methods of treating melanoma
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス, エルエルシー 肺がんを処置する方法
CN105209035A (zh) 2013-03-13 2015-12-30 阿布拉科斯生物科学有限公司 治疗儿童实体瘤的方法
JP6309610B2 (ja) 2013-03-14 2018-04-11 アブラクシス バイオサイエンス, エルエルシー 膀胱がんを処置する方法
US20170202782A1 (en) 2014-04-06 2017-07-20 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
US20180064679A1 (en) 2015-03-05 2018-03-08 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
JP2018521058A (ja) 2015-06-29 2018-08-02 アブラクシス バイオサイエンス, エルエルシー ナノ粒子mTOR阻害剤併用治療を使用して固形腫瘍を処置する方法
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
US20180177771A1 (en) 2015-06-29 2018-06-28 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
US20170181988A1 (en) 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer

Similar Documents

Publication Publication Date Title
JP2016513075A5 (enExample)
HRP20211062T1 (hr) Metode liječenja raka gušterače koje uključuju paklitaksel i gemcitabin
JP2016512506A5 (enExample)
HRP20160609T1 (hr) Postupci liječenja hepatocelularnog karcinoma
JP2013523656A5 (enExample)
HK1217292A1 (zh) 基於k- ras的突变状态治疗癌症的方法
JP2013518815A5 (enExample)
MY188911A (en) Methods of treating bladder cancer
JP2016138278A5 (enExample)
JP2016510748A5 (enExample)
JP2008274047A5 (enExample)
JP2018508593A5 (enExample)
JP2016520528A5 (enExample)
WO2014169078A3 (en) 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
JP2017005148A5 (enExample)
JP2019529520A5 (enExample)
RU2019105574A (ru) Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
WO2012081132A3 (en) Cosmetic composition in the form of an emulsion comprising small amount of emulsifier
JP2015146883A5 (enExample)
JP2012528186A5 (enExample)
JP2015511604A5 (enExample)
Stearns et al. Basal cell carcinoma of the prostate: a case report
JP2016502083A5 (enExample)
JP2016513722A5 (enExample)
MX383268B (es) Elemento de revestimiento de sarta de perforacion proporcionada con una capa de recarga, mejorada.